 | Up a level |
Pagan, Eleonora; Ruggeri, Monica; Bianco, Nadia; Bucci, Eraldo Oreste; Graffeo, Rossella; Borner, Markus; Giordano, Monica; Gianni, Lorenzo; Rabaglio, Manuela; Freschi, Andrea; Cretella, Elisabetta; Seles, Elena; Farolfi, Alberto; Simoncini, Edda; Ciccarese, Mariangela; Rauch, Daniel; Favaretto, Adolfo; Honecker, Friedemann; Berardi, Rossana; Franzetti-Pellanda, Alessandra; ... (2024). Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer. Breast, 77(103765), p. 103765. Elsevier 10.1016/j.breast.2024.103765
Ribi, Karin; Pagan, Eleonora; Sala, Isabella; Ruggeri, Monica; Bianco, Nadia; Bucci, Eraldo Oreste; Graffeo, Rossella; Borner, Markus; Giordano, Monica; Gianni, Lorenzo; Rabaglio, Manuela; Freschi, Andrea; Cretella, Elisabetta; Seles, Elena; Farolfi, Alberto; Simoncini, Edda; Ciccarese, Mariangela; Rauch, Daniel; Favaretto, Adolfo; Glaus, Agnes; ... (2023). Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland. Journal of Cancer Survivorship, 17(6), pp. 1847-1858. Springer 10.1007/s11764-022-01222-y
Peters, Solange; Danson, Sarah; Ejedepang, Dunson; Dafni, Urania; Hasan, Baktiar; Radcliffe, Hoi-Shen; Bustin, Frederique; Crequit, Jacky; Coate, Linda; Guillot, Monica; Surmont, Veerle; Rauch, Daniel; Rudzki, Jakob; O'Mahony, Deirdre; Barneto Aranda, Isidoro; Scherz, Amina; Tsourti, Zoi; Roschitzki-Voser, Heidi; Pochesci, Alessia; Demonty, Gaston; ... (2021). Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung cancer, 161, pp. 76-85. Elsevier 10.1016/j.lungcan.2021.09.002
Deressa, Biniyam Tefera; Assefa, Mathewos; Tafesse, Ephrem; Kantelhardt, Eva Johanna; Soldatovic, Ivan; Cihoric, Nikola; Rauch, Daniel; Jemal, Ahmedin (2021). Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia. BMC cancer, 21(1), p. 1102. BioMed Central 10.1186/s12885-021-08817-1
Moccia, Alden A; Taverna, Christian; Schär, Sämi; Vanazzi, Anna; Rondeau, Stéphanie; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Ruegsegger, Céline; Biaggi Rudolf, Christine; Rusterholz, Corinne; Hayoz, Stefanie; Ghielmini, Michele and Zucca, Emanuele (2020). Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood advances, 4(23), pp. 5951-5957. American Society of Hematology 10.1182/bloodadvances.2020002858
Benz, Rudolf; Arn, Kornelius; Andres, Martin; Pabst, Thomas; Baumann, Michael; Novak, Urban; Hitz, Felicitas; Hess, Urs; Zenhaeusern, Reinhard; Chalandon, Yves; Mey, Ulrich; Blum, Sabine; Rauch, Daniel; O'Meara Stern, Alix; Cantoni, Nathan; Bargetzi, Mario; Bianchi-Papina, Elena; Rossi, Davide; Passweg, Jakob; Lohri, Andreas; ... (2020). Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood advances, 4(15), pp. 3699-3707. American Society of Hematology 10.1182/bloodadvances.2020002160
Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; ... (2019). Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, pp. 82-91. Elsevier 10.1016/j.oraloncology.2019.08.004
Rothschild, Sacha I; Betticher, Daniel; Zenhäusern, Reinhard; Anchisi, Sandro; von Moos, Roger; Pless, Miklos; Moosmann, Peter; Popescu, Razvan A; Calderoni, Antonello; Dressler, Marco; Rauch, Daniel; Pederiva, Stefanie; Woelky, Regina; Papet, Claudia; Bühler, Vera; Borner, Markus (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer chemotherapy and pharmacology, 84(4), pp. 881-889. Springer 10.1007/s00280-019-03927-x
Burtness, Barbara; Haddad, Robert; Dinis, José; Trigo, José; Yokota, Tomoya; de Souza Viana, Luciano; Romanov, Ilya; Vermorken, Jan; Bourhis, Jean; Tahara, Makoto; Martins Segalla, José Getulio; Psyrri, Amanda; Vasilevskaya, Irina; Nangia, Chaitali Singh; Chaves-Conde, Manuel; Kiyota, Naomi; Homma, Akihiro; Holeckova, Petra; Del Campo, Josep Maria; Asarawala, Nirav; ... (2019). Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA oncology, 5(8), pp. 1170-1180. American Medical Association 10.1001/jamaoncol.2019.1146
Eliçin, Olgun; Sermaxhaj, Burim; Bojaxhiu, Beat; Shelan, Mohamed; Giger, Roland; Rauch, Daniel; Aebersold, Daniel (2019). Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients. Strahlentherapie und Onkologie, 195(6), pp. 468-474. Springer 10.1007/s00066-018-1400-5
Deressa, Biniyam Tefera; Cihoric, Nikola; Vlaskou Badra, Eugenia; Tsikkinis, Alexandros; Rauch, Daniel (2019). Breast cancer care in northern Ethiopia - cross-sectional analysis. BMC cancer, 19(1), p. 393. BioMed Central 10.1186/s12885-019-5612-6
Zucca, Emanuele; Rondeau, Stephanie; Vanazzi, Anna; Østenstad, Bjørn; Mey, Ulrich J. M.; Rauch, Daniel; Wahlin, Björn E.; Hitz, Felicitas; Hernberg, Micaela; Johansson, Ann-Sofie; de Nully Brown, Peter; Hagberg, Hans; Ferreri, Andrés J. M.; Lohri, Andreas; Novak, Urban; Zander, Thilo; Bersvendsen, Hanne; Bargetzi, Mario; Mingrone, Walter; Krasniqi, Fatime; ... (2019). Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 134(4), pp. 353-362. American Society of Hematology 10.1182/blood-2018-10-879643
von Moos, Roger; Koeberle, Dieter; Schacher, Sabina; Hayoz, Stefanie; Winterhalder, Ralph C; Roth, Arnaud; Bodoky, György; Samaras, Panagiotis; Berger, Martin D.; Rauch, Daniel; Saletti, Piercarlo; Plasswilm, Ludwig; Zwahlen, Daniel; Meier, Urs R; Yan, Pu; Izzo, Paola; Klingbiel, Dirk; Bärtschi, Daniela; Zaugg, Kathrin (2018). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). European journal of cancer, 89, pp. 82-89. Elsevier 10.1016/j.ejca.2017.11.005
Deressa, Biniyam Tefera; Rauch, Daniel; Vlaskou Badra, Eugenia; Glatzer, Markus; Jeremic, Branislav; Lössl, Kristina; Igrutinovic, Ivan; Cihoric, Nikola (2018). CURRENT STATUS OF CLINICAL TRIALS IN ETHIOPIA: HOW MUCH IS DONE? Ethiopian medical journal, 56(2), pp. 167-174. Ethiopian Medical Association
Stenner, Frank; Rothschild, Sacha I; Betticher, Daniel; Caspar, Clemens; Morant, Rudolf; Popescu, Razvan; Rauch, Daniel; Huber, Urs; Zenhäusern, Reinhard; Rentsch, Cyrill; Cathomas, Richard (2017). Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. (In Press). Clinical genitourinary cancer Elsevier 10.1016/j.clgc.2017.08.003
Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian (2017). Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical lung cancer, 18(3), pp. 303-309. Elsevier 10.1016/j.cllc.2016.11.007
Rosell, Rafael; Dafni, Urania; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massuti, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; ... (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The lancet. Respiratory medicine, 5(5), pp. 435-444. Elsevier 10.1016/S2213-2600(17)30129-7
Peters, Solange; Stahel, Rolf A; Dafni, Urania; Aix, Santiago Ponce; Massutí, Bartomeu; Gautschi, Oliver; Coate, Linda; López Martín, Ana; van Heemst, Robbert; Berghmans, Thierry; Meldgaard, Peter; Cobo Dols, Manuel; Noguera, Javier Garde; Curioni-Fontecedro, Alessandra; Rauch, Daniel; Mark, Michael T; Cuffe, Sinead; Biesma, Bonne; van Henten, Arjen Mj; Vidal, Óscar Juan; ... (2017). Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of thoracic oncology, 12(4), pp. 752-762. Elsevier 10.1016/j.jtho.2016.12.017
Cinieri, Saverio; Chan, Arlene; Altundag, Kadri; Vandebroek, An; Tubiana-Mathieu, Nicole; Barnadas, Agusti; Dodyk, Patricia; Lazzarelli, Silvia; Botha, Michiel; Rauch, Daniel; Villanova, Gustavo; Coskun, Ugur (2017). Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. Clinical breast cancer, 17(2), 91-99.e1. Elsevier 10.1016/j.clbc.2016.06.014
Gilli, Stefanie; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Rauch, Daniel; Pabst, Thomas (2017). BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of hematology, 96(3), pp. 421-429. Springer 10.1007/s00277-016-2900-y
Gautschi, O; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, Daniel; Pless, M; Froesch, P; Mach, N; Ochsenbein, Adrian (2016). 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. Journal of thoracic oncology, 11(4Suppl), S120-S120. Elsevier 10.1016/S1556-0864(16)30253-2
Taverna, Christian; Martinelli, Giovanni; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Vanazzi, Anna; Laszlo, Daniele; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Biaggi Rudolf, Christine; Rondeau, Stéphanie; Rusterholz, Corinne; Heijnen, Ingmar A F M; Zucca, Emanuele; Ghielmini, Michele (2016). Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. Journal of clinical oncology, 34(5), pp. 495-500. American Society of Clinical Oncology 10.1200/JCO.2015.61.3968
Eliçin, Olgun; Schmücking, Michael; Brömme, Jens; Rauch, Daniel; Ambarcioglu, Pinar; Plasswilm, Ludwig; Geretschläger, Andreas; Ghadjar, Pirus; Giger, Roland; Aebersold, Daniel (2016). Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis. JBUON, 21(1), pp. 175-181. Imprimatur Publications
Mueller, Beatrice U; Keller, Sandra; Seipel, Katja; Mansouri Taleghani, Behrouz; Rauch, Daniel; Betticher, Daniel; Egger, Thomas; Pabst, Thomas (2015). Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leukemia & lymphoma, 57(5), pp. 1122-1129. Informa Healthcare 10.3109/10428194.2015.1079315
Pless, Miklos; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A; Weder, Walter; Thierstein, Sandra; Gerard, Marie-Aline; Xyrafas, Alexandros; Früh, Martin; Cathomas, Richard; Zippelius, Alfred; Roth, Arnaud; Bijelovic, Milorad; Ochsenbein, Adrian; Meier, Urs R; Mamot, Christoph; Rauch, Daniel; Gautschi, Oliver; Betticher, Daniel C; Mirimanoff, René-Olivier; ... (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, 386(9998), pp. 1049-1056. Elsevier 10.1016/S0140-6736(15)60294-X
Baty, Florent; Rothschild, Sacha; Früh, Martin; Betticher, Daniel; Dröge, Cornelia; Cathomas, Richard; Rauch, Daniel; Gautschi, Oliver; Bubendorf, Lukas; Crowe, Susanne; Zappa, Francesco; Pless, Miklos; Brutsche, Martin; Swiss Group for Clinical Cancer Research, on behalf of the (2013). EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer. PLoS ONE, 8(9), e72966. Public Library of Science 10.1371/journal.pone.0072966
Früh, Martin; Cathomas, Richard; Siano, Marco; Tscherry, Gregor; Zippelius, Alfred; Mamot, Christoph; Erdmann, Andreas; Krasniqi, Fatima; Rauch, Daniel; Simcock, Mathew; Küttel, Erika; Fustier, Pierre; Pless, Miklos; Swiss Group for Clinical Cancer Research, (2013). Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clinical lung cancer, 14(1), pp. 34-39. Elsevier 10.1016/j.cllc.2012.04.001
Wyss, Etienne; Mueller-Garamvölgyi, Esther; Ghadjar, Pirus; Rauch, Daniel; Zbären, Peter; Arnold, Andreas (2013). Diagnosis and treatment outcomes for patients with lymphoma of the parotid gland. Laryngoscope, 123(3), pp. 662-9. Hoboken, N.J.: Wiley-Blackwell 10.1002/lary.23750
Helbling, D.; Bodoky, G.; Gautschi, O.; Sun, H.; Bosman, F.; Gloor, Beat; Burkhard, R.; Winterhalder, R.; Madlung, Axel; Rauch, Daniel; Saletti, P.; Widmer, L.; Borner, M.; Baertschi, D.; Yan, P.; Benhattar, J.; Leibundgut, Elisabeth O.; Bougel, S.; Koeberle, D. (2013). Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of oncology, 24(3), pp. 718-725. Oxford University Press 10.1093/annonc/mds519
Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715
Salzberg, Marc; Borner, Markus; Bauer, Jean-Alexandre; Morant, Rudolf; Rauch, Daniel; Rochlitz, Christoph (2006). Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. European journal of cancer, 42(15), pp. 2660-1. Amsterdam: Elsevier 10.1016/j.ejca.2006.06.009
Gick, Ute; Rochlitz, Christoph; Mingrone, Walter; Pestalozzi, Bernhard; Rauch, Daniel; Ballabeni, Pierluigi; Lanz, Doris; Hess, Viviane; Aebi, Stefan (2006). Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology - international journal of cancer research and treatment, 71(1-2), pp. 54-60. Basel: Karger 10.1159/000100449
Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
